Numedicus is pleased to announce the licensing of two key pieces of intellectual property, and associated know-how, around the use of an existing glutamate modulator, for the treatment of Rett Syndrome and opiate-induced respiratory depression, to AMO Pharma.
Monthly Archives: July 2017
18
Jul
Jul
The development of espindolol for the treatment of cancer cachexia entered a new phase this month, with the formation of a new spin out company Actimed Therapeutics.